Strategic Acquisition Evoke Neuroscience has recently been acquired by Firefly Neuroscience, signaling strong validation and potential cross-selling opportunities with Firefly’s AI-driven brain health platform and broader customer base.

Integrated Platform The Evoke EEG system and its ERP-based biomarkers can be positioned as a complementary module within a scalable cognitive electrophysiology platform, enabling upsell to clinics seeking end-to-end brain health assessment tools.

Clinical Differentiation With capabilities to detect subtle cognitive dysfunction and track treatment impact over time, there is opportunity to target neurology, psychiatry, and behavioral health practices that require objective biomarkers to support diagnosis and therapy monitoring.

Regulatory Credibility FDA-cleared Evoke EEG System provides a defensible selling point for hospitals and clinics pursuing standardized, evidence-based cognitive assessment, aiding procurement discussions and reimbursement conversations.

SMB Target Current size and revenue range (2–10 employees, $1M–$10M revenue) suggest a focus on small to mid-size clinics and private practices; tailor outreach to decision-makers in clinics expanding cognitive health services and neurodiagnostic capabilities.